¿¬°£Á¤º¸ ¼­ºñ½º
»óǰÄÚµå
941798

¹Ì±¹ÀÇ ¾È°úÀÇ : COVID-19 ½Çõ ¿µÇâ Á¶»ç - ½Ã¸®Áî 1(2020³â)

2020 US COVID-19 [Ophthalmologists] Practice Impact Surveys - Series 2

¹ßÇàÁ¤º¸: | ¸®¼­Ä¡»ç: Market Scope, LLC | ÆäÀÌÁö Á¤º¸: ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

2020³â 4¿ù 30ÀÏ¿¡ Market Scope, LLCÀÇ ¿Â¶óÀÎ Á¶»ç Æ÷Åп¡ µî·ÏµÈ ¹Ì±¹ÀÇ ¾È°úÀÇ 875¸íÀ» ´ë»óÀ¸·Î COVID-19ÀÇ Áø·á¡¤¼ö¼ú¿¡ ´ëÇÑ ¿µÇâ¿¡ °üÇÑ 4ºÎ ±¸¼º Á¶»çÀÇ Á¦1ºÎ¿¡ Âü°¡¸¦ ¿äûÇßÀ¸¸ç, 38°³ ÁÖ¿¡¼­ 123¸íÀÌ Âü°¡Çß°í ÀÀ´ä ºñÀ²Àº 14.1%¿´½À´Ï´Ù. ÀÌ Á¶»ç¿¡¼­´Â ¹é³»Àå ¼ö¼úÀ» ½ÃÇàÇϰí ÀÖ´Â Àǻ簡 67%, ³ì³»Àå ¼ö¼úÀ» ½ÃÇàÇϰí ÀÖ´Â Àǻ簡 32%, °¢¸· Ä¡·á¸¦ ½ÃÇàÇϰí ÀÖ´Â Àǻ簡 3%·Î ´Ù¾çÇÑ Àǻ簡 Âü°¡ÇßÀ¸¸ç, ´Ù¼ö´Â º¹¼ö ºÐ¾ß¿¡¼­ Ä¡·á¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. °³º° ÀÀ´äÀº ¸ðµÎ ±â¹Ð Á¤º¸·Î¼­ ¾öÁßÇÏ°Ô °ü¸®µÇ°í ÀÖÀ¸¸ç, Áý°è °á°ú¸¸À» º¸°íÇϰí ÀÖ½À´Ï´Ù. º» ¿¬°£Á¤º¸¼­ºñ½º´Â ÇâÈÄ 3°³¿ù°£ Áø·á¿Í ASCÀÇ Á÷Àå º¹±Í¡¤¼ö¼ú µ¿Çâ, ½Ã¼ú·® µîÀ» ºÐ¼®Çϱâ À§ÇØ Ãß°¡·Î 3°³ÀÇ Á¶»ç¸¦ ½ÃÇàÇÏ¿© Á¦°øÇÕ´Ï´Ù.

ÀÌ Á¶»ç ¸®Æ÷Æ®ÀÇ ³»¿ë

  • Áø·á¼Ò ÇöȲ
  • ½Ã¼ú ÇöȲ°ú °Ç¼ö ¿¹Ãø
  • ½Ã¼úÀÇ Àå±âÀûÀÎ ¿µÇâ
  • Áö¿ªº° ½Ã¼ú·®ÀÇ ÃßÀÌ
  • ASC Àç°³ ¿¹Á¤¿ù
  • ½Ã¼ú ÀÜ·®°ú ¿¹¾à ½ºÄÉÁÙ¸µ
  • ȯÀÚÀÇ Äµ½½°ú ¿¹¾à º¯°æ
  • ÇÁ¸®¹Ì¾ö IOL(¾È³» ·»Áî) ¼ö¼úÀÇ Ãßõ Æ÷ÀÎÆ®
  • ȯÀÚ °³¿ä
  • ¿î¿µ °èȹÀÇ ½Çõ
KSA 20.10.22

On October 30, 2020, Market Scope invited 891 US ophthalmologists via our online survey portal to participate in part seven of a nine-part series of surveys to capture the impact of COVID-19 on ophthalmic practices. There were 117 participants, representing 33 states. This survey attracted a diverse group of doctors; 85 percent of respondents provide cataract surgery, 63 percent perform glaucoma surgery, 29 percent treat retina patients, and 31 percent provide cornea treatment. Most of these doctors offer multiple areas of treatment. All individual responses are kept strictly confidential, and we report only aggregate data.

This survey report includes data on:

  • Office status
  • Procedure status and volume expectations
  • ASC analysis
  • Cataract specific analysis
  • Premium financing and LASIK
  • Capacity and capital equipment
  • Plans for pharmaceuticals
  • Long-term effects on practices
  • Telehealth changes
  • Practice operations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦